Logo image of CLGN

COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis

NASDAQ:CLGN - Nasdaq - IL0004960188 - Common Stock - Currency: USD

2.85  -0.03 (-1.04%)

Fundamental Rating

3

Taking everything into account, CLGN scores 3 out of 10 in our fundamental rating. CLGN was compared to 551 industry peers in the Biotechnology industry. The financial health of CLGN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CLGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLGN has reported negative net income.
CLGN had a negative operating cash flow in the past year.
In the past 5 years CLGN reported 4 times negative net income.
CLGN had negative operating cash flow in 4 of the past 5 years.
CLGN Yearly Net Income VS EBIT VS OCF VS FCFCLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -80.58%, CLGN is not doing good in the industry: 70.05% of the companies in the same industry are doing better.
CLGN's Return On Equity of -111.85% is in line compared to the rest of the industry. CLGN outperforms 43.01% of its industry peers.
Industry RankSector Rank
ROA -80.58%
ROE -111.85%
ROIC N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
CLGN Yearly ROA, ROE, ROICCLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

The Gross Margin of CLGN (48.71%) is better than 76.41% of its industry peers.
The Profit Margin and Operating Margin are not available for CLGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLGN Yearly Profit, Operating, Gross MarginsCLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLGN has about the same amount of shares outstanding.
Compared to 5 years ago, CLGN has more shares outstanding
There is no outstanding debt for CLGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLGN Yearly Shares OutstandingCLGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CLGN Yearly Total Debt VS Total AssetsCLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -6.77, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
CLGN has a Altman-Z score of -6.77. This is in the lower half of the industry: CLGN underperforms 66.42% of its industry peers.
CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.77
ROIC/WACCN/A
WACC9.07%
CLGN Yearly LT Debt VS Equity VS FCFCLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 4.48 indicates that CLGN has no problem at all paying its short term obligations.
The Current ratio of CLGN (4.48) is comparable to the rest of the industry.
CLGN has a Quick Ratio of 4.23. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
CLGN's Quick ratio of 4.23 is in line compared to the rest of the industry. CLGN outperforms 49.36% of its industry peers.
Industry RankSector Rank
Current Ratio 4.48
Quick Ratio 4.23
CLGN Yearly Current Assets VS Current LiabilitesCLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

CLGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -144.00%.
The Revenue for CLGN has decreased by -76.72% in the past year. This is quite bad
The Revenue for CLGN have been decreasing by -25.99% on average. This is quite bad
EPS 1Y (TTM)-144%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.86%
Revenue 1Y (TTM)-76.72%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1996.94%

3.2 Future

The Earnings Per Share is expected to grow by 22.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 73.05% on average over the next years. This is a very strong growth
EPS Next Y78.34%
EPS Next 2Y41.67%
EPS Next 3Y22.83%
EPS Next 5YN/A
Revenue Next Year546.26%
Revenue Next 2Y231.28%
Revenue Next 3Y73.05%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLGN Yearly Revenue VS EstimatesCLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
CLGN Yearly EPS VS EstimatesCLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLGN. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 279.41, which means the current valuation is very expensive for CLGN.
87.48% of the companies in the same industry are more expensive than CLGN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of CLGN to the average of the S&P500 Index (34.04), we can say CLGN is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 279.41
CLGN Price Earnings VS Forward Price EarningsCLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLGN Per share dataCLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CLGN does not grow enough to justify the current Price/Earnings ratio.
CLGN's earnings are expected to grow with 22.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.67%
EPS Next 3Y22.83%

More info and screens

0

5. Dividend

5.1 Amount

CLGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (8/8/2025, 8:26:21 PM)

2.85

-0.03 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-28 2025-05-28/bmo
Earnings (Next)08-21 2025-08-21
Inst Owners12.62%
Inst Owner Change-15.74%
Ins Owners30.05%
Ins Owner ChangeN/A
Market Cap36.25M
Analysts82.86
Price Target12.24 (329.47%)
Short Float %1.41%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-119.92%
Min EPS beat(2)-218.63%
Max EPS beat(2)-21.21%
EPS beat(4)0
Avg EPS beat(4)-76.23%
Min EPS beat(4)-218.63%
Max EPS beat(4)-21.21%
EPS beat(8)1
Avg EPS beat(8)296.42%
EPS beat(12)1
Avg EPS beat(12)161.42%
EPS beat(16)1
Avg EPS beat(16)99.24%
Revenue beat(2)0
Avg Revenue beat(2)-43.31%
Min Revenue beat(2)-62.78%
Max Revenue beat(2)-23.83%
Revenue beat(4)0
Avg Revenue beat(4)-56.16%
Min Revenue beat(4)-99.06%
Max Revenue beat(4)-23.83%
Revenue beat(8)1
Avg Revenue beat(8)-51.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.29%
PT rev (3m)-14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-366.67%
EPS NY rev (1m)-181.82%
EPS NY rev (3m)-181.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.82%
Revenue NY rev (1m)-7.83%
Revenue NY rev (3m)-7.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 279.41
P/S 14.67
P/FCF N/A
P/OCF N/A
P/B 2.92
P/tB 2.95
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)0.01
Fwd EY0.36%
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.19
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.58%
ROE -111.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.71%
FCFM N/A
ROA(3y)-51.39%
ROA(5y)-41.38%
ROE(3y)-66.85%
ROE(5y)-65.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.92%
Cap/Sales 16.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.48
Quick Ratio 4.23
Altman-Z -6.77
F-Score2
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)85.11%
Cap/Depr(5y)108.12%
Cap/Sales(3y)180.83%
Cap/Sales(5y)112.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-144%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.86%
EPS Next Y78.34%
EPS Next 2Y41.67%
EPS Next 3Y22.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-76.72%
Revenue growth 3Y-67.95%
Revenue growth 5Y-25.99%
Sales Q2Q%1996.94%
Revenue Next Year546.26%
Revenue Next 2Y231.28%
Revenue Next 3Y73.05%
Revenue Next 5YN/A
EBIT growth 1Y-75.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.87%
OCF growth 3YN/A
OCF growth 5YN/A